PremiumCompany AnnouncementsMolecular Partners Reports 2024 Earnings and Strategic Progress Molecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M Molecular Partners, Orano Med announce presentation of MP0712 data PremiumThe FlyMolecular Partners AG (ADR) trading resumes Molecular Partners AG (ADR) trading halted, volatility trading pause Molecular Partners AG (ADR) trading resumes PremiumThe FlyMolecular Partners, Orano Med enter pact to develop Radio-DARPin therapeutics Molecular presents data from dosing cohorts of Phase 1/2a trial of MP0533 Molecular Partners price target lowered by CHF 2 at JPMorgan